期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 95, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2021.107515
关键词
AIDS; RAG complex; Human immunodeficiency Virus; V(D)J recombination; Immunodeficiency; Retrovirus
资金
- DBT-COE [BT/PR/3458/COE/34/33/2015]
- IIScDBT partnership programme [BT/PR27952INF/22/212/2018]
- Senior Research Fellowship (SRF) from IISc
Inhibitors targeting HIV integrase can interfere with the binding and cleavage of RAG, hindering its physiological functions, providing a new avenue for HIV treatment.
Multiple steps of the retroviral infection process have been targeted over the years to develop therapeutic approaches, starting from the entry of the virus into the cell till the viral DNA integration to host genome. Inhibitors against the Human Immunodeficiency Virus (HIV) integrase is the newest among the therapies employed against HIV. Recombination activating gene 1 (RAG1) is an integral protein involved in the generation of diversity of antibodies and T-cell receptors and is one of the partners of the RAG complex. Studies have shown structural and functional similarities between the HIV integrase and RAG1. Recently, we and others have shown that some of the integrase inhibitors can interfere with RAG binding and cleavage, hindering its physiological functions. This mini review focuses on the HIV integrase, integrase inhibitors and their effect on RAG activities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据